These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16848687)

  • 1. Inhibiting angiogenesis: interview with Dr Jean Plouët. Interview by Emma Quigley.
    Plouët J
    Expert Opin Ther Targets; 2006 Aug; 10(4):501-3. PubMed ID: 16848687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In memoriam: Jean Blancou, DVM, 1936-2010. World authority on rabies, historian and former Director General of the World Organisation for Animal Health (Office International des Épizooties: OIE).
    Vet Ital; 2011; 47(1):105-6. PubMed ID: 21240856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Napoleone Ferrara and the saga of vascular endothelial growth factor.
    Ribatti D
    Endothelium; 2008; 15(1):1-8. PubMed ID: 18568940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic potential of CD39: interview with Dr Simon Robson by Emma Quigley.
    Robson S
    Expert Opin Ther Targets; 2006 Oct; 10(5):649-52. PubMed ID: 16981822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell adhesion molecules as therapeutic targets: interview with Professor Michael P Schön. Interviewed by Emma Quigley.
    Schön MP
    Expert Opin Ther Targets; 2006 Dec; 10(6):799-802. PubMed ID: 17105368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti.
    Ferrara N
    Int J Dev Biol; 2011; 55(4-5):383-8. PubMed ID: 21858763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic drugs to treat human disease: an interview with Napoleone Ferrara by Kristin H. Kain.
    Ferrara N
    Dis Model Mech; 2009; 2(7-8):324-5. PubMed ID: 19553691
    [No Abstract]   [Full Text] [Related]  

  • 10. Vascular endothelial growth factor: biology and therapeutic applications.
    Ho QT; Kuo CJ
    Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity.
    Gensicka M; Głowacka A; Dzierzbicka K; Cholewinski G
    Curr Med Chem; 2015; 22(33):3830-47. PubMed ID: 26337104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dr. John Baptiste Edouard Gélineau].
    Janković S; Susić V; Sokić D; Lević Z
    Srp Arh Celok Lek; 1996; 124(11-12):331-5. PubMed ID: 9132972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
    Thanigaimani S; Kichenadasse G; Mangoni AA
    Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current targets in irritable bowel syndrome: an interview with Eamonn Quigley. Interview by Emma Quigley.
    Quigley E
    Expert Opin Ther Targets; 2006 Jun; 10(3):351-3. PubMed ID: 16706675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
    Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A conversation with Napoleone Ferrara.
    Ferrara N; Neill US
    J Clin Invest; 2014 Aug; 124(8):3275-6. PubMed ID: 25083827
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
    Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.